The National Organization for Rare Disorders (NORD) is seeking participants for its survey-based study Living Rare, which aims to better understand the real-world lived experiences of people in the U.S. with rare diseases. Living Rare, the first large-scale study of its kind in the U.S., seeks to capture the…
FT011, Certa Therapeutics’ oral treatment candidate for systemic sclerosis (SSc), will now be known under the generic name asengeprast. That decision was made by the World Health Organization (WHO), which is responsible for assigning International Non-Proprietary Names, or INNs, to pharmaceutical substances or active ingredients. INNs are globally…
Ferroptosis, a cell death process that can help to regulate uncontrolled cell growth, was suppressed in skin cells from people with systemic sclerosis (SSc), according to recent research. Such suppression appears to be mediated by increased activity of an antioxidant protein called GPX4. Researchers believe that targeting GPX4 to…
Researchers have developed a model for predicting which systemic sclerosis (SSc) patients with interstitial lung disease (ILD) — together known as SSc-ILD — will experience progressive lung function declines that are known to be associated with a poorer prognosis. The prediction algorithm accounts for nine clinical factors, including…
A non-invasive technique called flow-mediated dilation (FMD) could be useful for monitoring blood vessel alterations in people with systemic sclerosis (SSc) and predicting the likelihood of certain blood flow (vascular) complications, a study has found. The test findings show distinct differences between SSc patients and healthy people, and were…
Antibodies designed to neutralize the protein galectin-3 (Gal-3) eased scarring and inflammation in a mouse model of systemic sclerosis (SSc), a recent study shows. Gene activity related to Gal-3 and the proteins it interacts with were found to be strongly associated with disease severity, lung and heart malfunction, and…
Aisa Pharma has launched the second part of its Phase 2a trial evaluating Profervia (cilnidipine) — an oral medication that showed positive safety and efficacy data in the study’s first part — as a treatment for Raynaud’s phenomenon in people with systemic sclerosis (SSc). Raynaud’s is…
Certain metabolic changes in the blood could serve as biomarkers for systemic sclerosis (SSc), according to a recent analysis. In “the largest metabolic study in SSc so far,” researchers identified metabolites — small molecules that are products of metabolism — that distinguished SSc patients from healthy adults, but were…
An analysis of genetic data from patient skin samples revealed four genes that may be involved in the development or progression of systemic sclerosis (SSc), as well as regulatory molecules that also might contribute. The scientists believe these four genes — SERPINE1, CCL2, IL6, and ISG15 — could be…
The National Scleroderma Foundation has awarded a $200,000 research grant to a University of Minnesota scientist to study how immune system responses drive the emergence of scleroderma — the cause of which remains unknown. The funding for researcher Rafael Contreras-Galindo, PhD, comes in the form of the two-year…
Get regular updates to your inbox.